ProShare Advisors
WINT

ProShare Advisors’s Windtree Therapeutics Inc WINT Stock Holding History

ProShare Advisors’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-2,477
Closed -$53K – 2571
2013
Q2 		$53K Buy
+2,477
New +$61K ﹤0.01% 2353

Other funds holding WINT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ProShare Advisors's WINT Position: Q3 2013 in Review

ProShare Advisors sold out of Windtree Therapeutics Inc (WINT) in Q3 2013, closing a stake of 2,477 shares — an estimated $53K sold.

ProShare Advisors first reported a position in WINT in Q2 2013 and held it in 1 quarter. The position peaked at $53K in Q2 2013. 50 funds tracked by Wall St. Rank hold WINT as of Q3 2013.

  • ProShare Advisors reported no remaining Windtree Therapeutics Inc position as of Q3 2013 after selling out during the quarter.
  • ProShare Advisors sold 2,477 Windtree Therapeutics Inc shares in Q3 2013, an estimated $53K.
  • ProShare Advisors first reported a position in Windtree Therapeutics Inc in Q2 2013 and held it in 1 quarter.
  • ProShare Advisors's Windtree Therapeutics Inc position peaked at $53K in Q2 2013.
  • 50 funds tracked by Wall St. Rank held Windtree Therapeutics Inc as of Q3 2013.

Based on ProShare Advisors's 13F filing for Q3 2013, filed 7 Nov 2013.